Abstract 2969: Histone deacetylase (HDAC) inhibitors exhibit antitumor activity in triple negative breast cancer via suppression of HER3 triggered signaling

Authors

• Sanbao Ruan, LSU Health Sciences Center - New Orleans
• Hao Liu, Guangzhou Medical University, Guangzhou, CN
• Hui Lyu, LSU Health Sciences Center - New OrleansFollow
• Congcong Tan, LSU Health Sciences Center - New OrleansFollow
• Bolin Liu, LSU Health Sciences Center - New OrleansFollow

Document Type

Conference Proceeding

Publication Date

6-15-2022

Publication Title

Cancer Research

Abstract

Proceedings of the American Association for Cancer Research Annual Meeting 2022; Apr 8 - 13, 2022; Philadelphia, PA

Volume

82

Issue

12, Supplement

Publisher

American Association for Cancer Research

Comments

Abstract 2969

Rights

©2022 American Association for Cancer Research

Recommended Citation

Ruan, Sanbao; Liu, Hao; Lyu, Hui; Tan, Congcong; and Liu, Bolin, "Abstract 2969: Histone deacetylase (HDAC) inhibitors exhibit antitumor activity in triple negative breast cancer via suppression of HER3 triggered signaling" (2022). School of Graduate Studies Faculty Publications. 553.
https://digitalscholar.lsuhsc.edu/sogs_facpubs/553
10.1158/1538-7445.AM2022-2969